Anti-aromatase pharmaceutical composition for controlling...

Drug – bio-affecting and body treating compositions – Plant material or plant extract of undetermined constitution... – Containing or obtained from prunus

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S725000, C424S775000

Reexamination Certificate

active

06607755

ABSTRACT:

It is known, that throughout life of a mammal or a human being, testosterone/estrone ratios do have a considerable effect on mammal or human life.
This testosterone/estrone ratio will exert a powerful and considerable reactions to the emotional well being, as well as in sexual functions, libido, muscle mass and strength, energy, cardiovascular health, bone integrity and memory behavior.
It is advantageous that testosterone/estrogen ratio is directly influenced by the aromitazation and bioavailable levels of several other hormones, including DHEA projesterone, androstenedione, estrone aldosterone, cortisol, estradiol and dihydrotestoasterone. These hormones which directly effect testosterone and estrogen ratios, also directly effect emotional well being, as well as sexual function, libido, muscle mass, fat to lean muscle ratios, strength, energy, cardiovascular health, osteoporosis, memory and cognitive function, as well as risk for breast cancer and benign prostate hypertrophy.
It is well established, that as a human being ages, these testosterone/estrone ratios adjust and change with age, with increasing formation levels of estrone and a proportional decrease in the formation of testosterone.
It is known for the specification of U.S. Pat. No. 4,598,072 to Schweibert etal dated Jul. 1, 1986 to provide for an aromatase inhibitor and an antiandrogen which generally is applicable for the treatment of prostatic hyperglania, incorporated herein by reference only.
Furthermore, it is known for the specification of U.S. Pat. No. 5,972,921 to Santti et.al dated Oct. 26, 1999 in the use of an aromatase inhibitor administered for the specific treatment for men for detrusor wrethral dyssynergia. This is in corporated herein for reference only.
It is also known for the specification of U.S. Pat. No. 5,861,389 to Radlmaier et.al dated Jan. 19,1999 for specific treatment of only androgen deficiency in men using selective aromatase inhibitors. This is in corporated herein for reference only.


REFERENCES:
patent: 4598072 (1986-07-01), Schweibert
patent: 5284873 (1994-02-01), Salinero-Rodero et al.
patent: 5861389 (1999-01-01), Radlmeier
patent: 5972921 (1999-10-01), Santti
patent: 6039950 (2000-03-01), Khwaija et al.
patent: 2001/0008638 (2001-07-01), Wilding

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Anti-aromatase pharmaceutical composition for controlling... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-aromatase pharmaceutical composition for controlling..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-aromatase pharmaceutical composition for controlling... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3090256

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.